HC Wainwright Reiterates Buy Rating for Dyne Therapeutics (NASDAQ:DYN)
HC Wainwright reiterated their buy rating on shares of Dyne Therapeutics (NASDAQ:DYN – Free Report) in a report published on Monday,Benzinga reports. They currently have a $46.00 price objective on the stock. Other research analysts have also issued research reports about the stock. Royal Bank of Canada reiterated an “outperform” rating and issued a $45.00 […]
HC Wainwright reiterated their buy rating on shares of Dyne Therapeutics (NASDAQ:DYN – Free Report) in a report published on Monday,Benzinga reports. They currently have a $46.00 price objective on the stock. Other research analysts have also issued research reports about the stock. Royal Bank of Canada reiterated an “outperform” rating and issued a $45.00 […]
